Our advanced robotic CyberKnife systems (M6 and S7) enable highly precise radiosurgical treatment of benign and malignant tumors, as well as selected metastases, in different regions of the body.
The treatment is non-invasive and, in appropriately selected patients, may provide an alternative to surgery or conventional forms of radiation therapy.
Each treatment is individually planned and precisely tailored to the specific condition, tumor location, and personal clinical situation.
CyberKnife is a highly precise, non-invasive radiosurgical treatment system that, despite its name, requires neither a scalpel nor a visible skin incision.
The system can compensate for movement, such as respiratory motion, in real time and is also suitable for highly sensitive anatomical regions, for example tumors adjacent to the optic nerve.
During treatment, highly focused photon radiation is delivered to the target from multiple angles with exceptional precision. The therapeutic dose converges within the diseased tissue.
Over the subsequent course, tumor regression may occur, typically over a period of several weeks.
This approach maximizes the protection of surrounding healthy tissue.
The ERCM currently operates two state-of-the-art CyberKnife systems: the M6 and the S7.
If your individual clinical situation is suitable for non-invasive CyberKnife treatment, therapy is performed on an outpatient basis and can usually be arranged promptly.
The precision of our treatment, with highly targeted ablation of diseased tissue, enables effective tumor control. Tumor control rates exceed 90%.
Each treatment session is performed on an outpatient basis and takes approximately 15 to 30 minutes.
An inpatient hospital stay or subsequent rehabilitation is not required. This allows you to return to your usual daily activities quickly.
Precision robotics
Digital image-guidance system
Respiratory motion compensation
Depending on factors such as tumor size and location, kidney cancers and adrenal metastases can often be effectively treated using modern radiosurgery.
CyberKnife treatment can be used for lung cancers, particularly early-stage disease (T1 and T2), as well as for lung metastases when only a small number of smaller lesions are present.
Primary liver tumors and, in particular, liver metastases have been successfully treated with the CyberKnife method for many years in selected cases.
In selected clinical situations, benign and malignant spinal tumors are suitable indications for high-precision treatment with CyberKnife.
As an alternative to surgery or conventional radiotherapy, selected prostate cancers can be effectively treated using the CyberKnife method.
CyberKnife technology can be used to treat a wide range of benign and malignant brain tumors and other intracranial conditions.
Solitary lymph-node metastases can be effectively treated with radiosurgery in a variety of clinical situations.
We know how important time is to you. That is why we clarify promptly whether CyberKnife treatment is suitable for your individual situation. You remain fully involved throughout the process: at the ERCM, individual treatment options are always discussed with you and with a multidisciplinary treatment team.
Gamma Knife treatment was established in Germany in 1994 and was already being performed in Munich at that time.
Gamma Knife was used exclusively for the treatment of conditions affecting the brain. To achieve its very high precision, a rigid head frame was generally fixed to the skull. CyberKnife has been available at the ERCM's current location since 2005; the M6 system has since been complemented by a second state-of-the-art system, the S7, since January 2026. CyberKnife enables high-precision radiotherapy throughout the body. Dynamic position correction and advanced respiratory tracking allow the target to be treated with maximum spatial accuracy throughout the entire treatment session.
CyberKnife treatment is generally very well tolerated. Most patients experience no side effects or only mild, temporary effects from which they recover quickly. Depending on the body region being treated and the size of the tumor, possible side effects may include headache, nausea or fatigue. In rare cases, temporary tissue swelling may occur after treatment. This can usually be controlled effectively with medication.
Treatment is performed on an outpatient basis, and you can leave the ERCM independently shortly after the procedure.
Follow-up examinations are required after 3 to 6 months. Regular clinical assessments and imaging studies are used to document the course of treatment and recovery. Any necessary examinations can be carried out here in our immediate vicinity or close to your home, with subsequent transfer of the imaging data to us.
For many tumors, a single CyberKnife treatment is sufficient. Depending on the type, size and location of the tumor, it may be appropriate to divide CyberKnife treatment into several sessions. If new tumors or metastases develop after the initial treatment, radiosurgical treatment can also be performed again. This approach is well established and is part of standard clinical practice.
Direct agreements for full reimbursement of CyberKnife treatment are in place with almost all private health insurers and with a growing number of statutory health insurers. These include AOK Bayern, LKK, KKH and most Bavarian BKK health insurance funds. If prior authorization for reimbursement is required before treatment in your individual case, we will be happy to assist you with the application.
The exact schedule will be discussed with you individually and communicated well in advance of treatment. If you are travelling to us from outside Munich, we will be happy to assist you with the practical planning and organization of your stay and treatment.
Modern treatment options require individualized decision-making based on the disease, expected outcomes, quality of life, and each patient’s personal priorities.
We support patients in identifying the most appropriate treatment approach. For enquiries, please use our contact form, or call us directly.